Safety evaluation of selective RET inhibitors in patients with lung cancer: a real-world pharmacovigilance study
This study provides critical insights into the established and potential adverse events associated with selpercatinib and pralsetinib. The findings offer valuable evidence to guide the clinical use of RET inhibitors.
Authors
- Leilei Wu
- Yang-Tui Cheng
- Wenmei Jiang (ORCID: https://orcid.org/0000-0002-9449-1626)
- C. Yu
- Qian Dong
- Jue Shen
- Junnan Ru
- Yaokai Wang
Institutions
- Shenzhen University (CN)
- University Town of Shenzhen (CN)
- Zhejiang Cancer Hospital (CN)
- Shenzhen University Health Science Center (CN)
- Hangzhou Cancer Hospital (CN)
Publication Details
- Journal
- Tumori Journal
- Published
- 2026-02-06
- DOI
- https://doi.org/10.1177/03008916251414316
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00